Literature DB >> 27766224

Improvement of Meloxicam Solubility Using a β-Cyclodextrin Complex Prepared via the Kneading Method and Incorporated into an Orally Disintegrating Tablet.

Ahmad Ainurofiq1, Syaiful Choiri1, Muhamad Ali Azhari2, Chaterin Romauli Siagian2, Bambang Budi Suryadi2, Fea Prihapsara2, Sholichah Rohmani2.   

Abstract

Purpose: The aim of this research was to formulate and develop an orally disintegrating tablet (ODT) that incorporated a MEL/β-CD complex, using a quality by design (QbD) approach to enhance solubility and drug release.
Methods: Multiple regression linear analysis was conducted to develop the kneading process and ODT formulation. Mixing time and amount of solvent were used as independent variables in kneading process optimisation, while the superdisintegrants were used to obtain the desired formulation. Fourier transform infrared spectroscopy and differential scanning calorimetry were performed for complex characterization.
Results: MEL/β-CD complexation was successful in enhancing MEL solubility. The results suggest that increasing the amount of solvent and mixing time enhances drug loading and drug release. However, increased solvent amounts present the problem of removing the solvent. Primojel and Polyplasdone had a significant effect on the water wicking and tablet disintegration process (p<0.05), although Polyplasdone negatively affected tablet hardness. Both an optimized KN process and ODT formulation were obtained using a QbD approach.
Conclusion: Incorporation of the MEL/β-CD complex during ODT formulation using the QbD approach serves as a model for ODT product development, with optimal product performance based on the specification of quality target product profiles. To understand more specific phenomena, one point in the middle of the design for each factor should be added to more powerfully estimate this effect and avoid the lack of estimate due to an inadequate equation.

Entities:  

Keywords:  Kneading; Meloxicam; Orally disintegrating tablet; Quality by design; β-cyclodextrin

Year:  2016        PMID: 27766224      PMCID: PMC5071803          DOI: 10.15171/apb.2016.052

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  12 in total

1.  Evolution of the interaction of a new chemical entity, eflucimibe, with gamma-cyclodextrin during kneading process.

Authors:  A Gil; A Chamayou; E Leverd; J Bougaret; M Baron; G Couarraze
Journal:  Eur J Pharm Sci       Date:  2004-10       Impact factor: 4.384

Review 2.  Cyclodextrins.

Authors:  Sergey V Kurkov; Thorsteinn Loftsson
Journal:  Int J Pharm       Date:  2012-07-05       Impact factor: 5.875

3.  For the special IJP issue "poorly soluble drugs".

Authors:  Thorsteinn Loftsson; Anette Muellertz; Juergen Siepmann
Journal:  Int J Pharm       Date:  2013-06-03       Impact factor: 5.875

4.  Aerosil as a novel co-crystal co-former for improving the dissolution rate of hydrochlorothiazide.

Authors:  Sanaa A El-Gizawy; Mohamed A Osman; Mona F Arafa; Gamal M El Maghraby
Journal:  Int J Pharm       Date:  2014-12-18       Impact factor: 5.875

5.  Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation.

Authors:  Ziyaur Rahman; Akhtar Siddiqui; Mansoor A Khan
Journal:  Eur J Pharm Biopharm       Date:  2013-06-22       Impact factor: 5.571

6.  Functionality of disintegrants and their mixtures in enabling fast disintegration of tablets by a quality by design approach.

Authors:  Parind Mahendrakumar Desai; Patrick Xuan Hua Er; Celine Valeria Liew; Paul Wan Sia Heng
Journal:  AAPS PharmSciTech       Date:  2014-05-22       Impact factor: 3.246

7.  Development of nanocrystal formulation of meloxicam with improved dissolution and pharmacokinetic behaviors.

Authors:  Masanori Ochi; Takaki Kawachi; Eri Toita; Issei Hashimoto; Kayo Yuminoki; Satomi Onoue; Naofumi Hashimoto
Journal:  Int J Pharm       Date:  2014-08-17       Impact factor: 5.875

8.  Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.

Authors:  Sunil Prabhu; Maru Ortega; Chan Ma
Journal:  Int J Pharm       Date:  2005-09-14       Impact factor: 5.875

9.  Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation.

Authors:  Ziyaur Rahman; Ahmed S Zidan; Mansoor A Khan
Journal:  Int J Pharm       Date:  2010-08-27       Impact factor: 5.875

10.  The influence of the preparation methods on the inclusion of model drugs in a beta-cyclodextrin cavity.

Authors:  P J Salústio; G Feio; J L Figueirinhas; J F Pinto; H M Cabral Marques
Journal:  Eur J Pharm Biopharm       Date:  2008-10-17       Impact factor: 5.571

View more
  2 in total

1.  Assessment of the Effect of PLGA Co-polymers and PEG on the Formation and Characteristics of PLGA-PEG-PLGA Co-block Polymer Using Statistical Approach.

Authors:  Teuku Nanda Saifullah Sulaiman; Dwi Larasati; Akhmad Kharis Nugroho; Syaiful Choiri
Journal:  Adv Pharm Bull       Date:  2019-08-01

2.  Understanding the effect of lipid formulation loading and ethanol as a diluent on solidification of pitavastatin super-saturable SNEDDS using factorial design approach.

Authors:  Ilham Kuncahyo; Syaiful Choiri; Achmad Fudholi; Abdul Rohman; Ronny Martien
Journal:  Res Pharm Sci       Date:  2019-10-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.